Effects of somatostatin analogues on retinal angiogenesis in a mouse model of oxygen-induced retinopathy: Involvement of the somatostatin receptor subtype 2

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 8, 2009, Pages 3596-3606

  Monte, Massimo Dal ^a   Ristori, Chiara ^a   Cammalleri, Maurizio ^a   Bagnoli, Paola ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYANAMID 154806; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; CYN 154806; DEXTRAN; FLUORESCEIN DERIVATIVE; FLUORESCEIN DEXTRAN; FLUORESCEIN-DEXTRAN; OLIGOPEPTIDE; OXYGEN; SOMATOSTATIN RECEPTOR; SSTR2 PROTEIN, MOUSE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HYPOXIA; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA NEOVASCULARIZATION; UPREGULATION; WILD TYPE; ANIMAL; ANOXIA; C57BL MOUSE; DRUG ANTAGONISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; GENETICS; HUMAN; METABOLISM; MOUSE MUTANT; NEWBORN; PATHOLOGY; RETROLENTAL FIBROPLASIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBCUTANEOUS DRUG ADMINISTRATION; WESTERN BLOTTING;

ANIMALS; ANIMALS, NEWBORN; ANOXIA; BLOTTING, WESTERN; DEXTRANS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCEINS; HUMANS; INFANT, NEWBORN; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, FLUORESCENCE; OCTREOTIDE; OLIGOPEPTIDES; OXYGEN; RECEPTORS, SOMATOSTATIN; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 68349093931     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-3412     Document Type: Article

References (57)

1. Hoyer D, Bell GI, Berelowitz M, et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci. 1995;16:86-88.
2. Cervia D, Casini G, Bagnoli P. Physiology and pathology of somatostatin in the mammalian retina: a current view. Mol Cell Endocrinol.2008;286:112-122.
3. Boehm BO. Use of long-acting somatostatin analogue treatment in diabetic retinopathy. Dev Ophthalmol. 2007;39:111-121.
4. Dasgupta P. Somatostatin analogues: multiple roles in cellular proliferation,neoplasia, and angiogenesis. Pharmacol Ther. 2004;102:61-85.
5. Aydede H, Seda Vatansever H, Erhan Y, Ilkgül O. Effects of ocreotide on intestinal mucosa in rats with portal hypertensive enteropathy. Acta Histochem. 2009;111:74-82.
6. Mejias M, Garcia-Pras E, Tiani C, Bosch J, Fernandez M. The somatostatin analogue octreotide inhibits angiogenesis in the earliest, but not in advanced, stages of portal hypertension in rats. J Cell Mol Med. 2008;12:1690-1699.
7. Palii SS, Caballero S Jr., Shapiro G, Grant MB. Medical treatment of diabetic retinopathy with somatostatin analogues. Expert Opin Investig Drugs. 2007;16:73-82.
8. Grant MB, Caballero S Jr. The potential role of octreotide in the treatment of diabetic retinopathy. Treat Endocrinol. 2005;4:199-203.
9. Palii SS, Afzal A, Shaw LC, et al. Nonpeptide somatostatin receptor agonists specifically target ocular neovascularization via the somatostatin type 2 receptor. Invest Ophthalmol Vis Sci. 2008;49: 5094-5102.
10. Wilkinson-Berka JL, Lofthouse S, Jaworski K, Ninkovic S, Tachas G, Wraight CJ. An antisense oligonucleotide targeting the growth hormone receptor inhibits neovascularization in a mouse model of retinopathy. Mol Vis. 2007;13:1529-1538.
11. Higgins MD, Yan Y, Schrier BK. Somatostatin analogs inhibit neonatal retinal neovascularization. Exp Eye Res. 2002;74:553-559.
12. Dal Monte M, Cammalleri M, Martini D, Casini G, Bagnoli P. Antiangiogenic role of somatostatin receptor 2 in a model of hypoxia-induced neovascularization in the retina: results from transgenic mice. Invest Ophtalmol Vis Sci. 2007;48:3480-3489.
13. Casini G, Dal Monte M, Petrucci C, et al. Altered morphology of rod bipolar cell axonal terminals in the retinas of mice carrying genetic deletion of somatostatin subtype receptor 1 or 2. Eur J Neurosci. 2004;19:43-54.
14. Dal Monte M, Petrucci C, Vasilaki A, et al. Genetic deletion of somatostatin receptor 1 alters somatostatinergic transmission in the mouse retina. Neuropharmacology. 2003;45:1080-1092.
15. Allen JP, Hathway GJ, Clarke NJ, et al. Somatostatin receptor 2 knockout/lacZ knockin mice show impaired motor coordination and reveal sites of somatostatin action within the striatum. Eur J Neurosci. 2003;17:1881-1895.
16. Kreienkamp HJ, Akgun E, Baumeister H, Meyerhof W, Richter D. Somatostatin receptor subtype 1 modulates basal inhibition of growth hormone release in somatotrophs. FEBS Lett. 1999;462:464-466.
17. Smith LEH, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35:101-111.
18. Nunn C, Schoeffer P, Langenegger D, Hoyer D. Functional characterization of the putative somatostatin sst2 receptor antagonist CYN 154806. Naunyn Schmiedebergs Arch Pharmacol. 2003;367:1-9.
19. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov. 2003;2:999-1017.
20. Liao Z, Li ZS, Lu Y, Wang WZ. Microinjection of exogenous somatostatin in the dorsal vagal complex inhibits pancreatic secretion via somatostatin receptor-2 in rats. Am J Physiol Gastrointest Liver Physiol. 2007;292:G746-G752.
21. Tulipano G, Rossi E, Culler MD, et al. The somatostatin subtype-2 receptor antagonist, BIM-23627, improves the catabolic effects induced by long-term glucocorticoid treatment in the rat. Regul Pept. 2005;125:85-92.
22. Stumm RK, Zhou C, Schulz S, et al. Somatostatin receptor 2 is activated in cortical neurons and contributes to neurodegeneration after focal ischemia. J Neurosci. 2004;24:11404-11415.
23. Tulipano G, Soldi D, Bagnasco M, et al. Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454 effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment. Endocrinology. 2002;143:1218-1224.
24. Booth CE, Kirkup AJ, Hicks GA, Humphrey PP, Grundy D. Somatostatinsst(2) receptor-mediated inhibition of mesenteric afferent nerves of the jejunum in the anesthetized rat. Gastroenterology.2001;121:358-369.
25. D'Amato R, Wesolowski E, Smith LE. Microscopic visualization of the retina by angiography with high-molecular-weight fluoresceinlabeled dextrans in the mouse. Microvasc Res. 1993;46:135-142.
26. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 2000;132:365-386.
27. Wang X, Seed B. A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res. 2003;31:e154.
28. Pattyn F, Speleman F, De Paepe A, Vandesompele J. RTPrimerDB: the real-time PCR primer and probe database. Nucleic Acids Res. 2003;31:122-123.
29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-408.
30. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal Biochem. 1976;72:248-254.
31. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
32. Nagai N, Izumi-Nagai K, Oike Y, et al. Suppression of diabetesinduced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kB pathway. Invest Ophthalmol Vis Sci. 2007;48:4342-4350.
33. Obrosova IG, Drel VR, Kumagai AK, Szabo C, Pacher P, Stevens MJ. Early diabetes-induced biochemical changes in the retina:comparison of rat and mouse models. Diabetologia. 2006;49:2525-2533.
34. Dejneka NS, Kuroki AM, Fosnot J, Tang W, Tolentino MJ, Bennett J. Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis. 2004;10:964-972.
35. Elner SG, Elner VM, Yoshida A, Dick RD, Brewer GJ. Effects of tetrathiomolybdate in a mouse model of retinal neovascularization.Invest Ophthalmol Vis Sci. 2005;46:299-303.
36. Cervia D, Nunn C, Bagnoli P. Multiple signalling transduction mechanisms differentially coupled to somatostatin receptor subtypes: a current view. Curr Enz Inhib. 2005;1:265-279.
37. Pavan B, Fiorini S, Dal Monte M, et al. Somatostatin coupling to adenylyl cyclase activity in the mouse retina. Naunyn-Schmiedeberg's Arch Pharmacol. 2004;370:91-98.
38. Stragier B, Clinckers R, Meurs A, et al. Involvement of the somatostatin-2 receptor in the anti-convulsant effect of angiotensin IV against pilocarpine-induced limbic seizures in rats. J Neurochem.2006;98:1100-1113.
39. Hathway GJ, Humphrey PP, Kendrick KM. Evidence that somatostatin sst2 receptors mediate striatal dopamine release. Br J Pharmacol. 1999;128:1346-1352.
40. Cervia D, Martini D, Ristori C, et al. Modulation of the neuronal response to ischaemia by somatostatin analogues in wild-type and knock-out mouse retinas. J Neurochem. 2008;106:2224-2235.
41. Schwartkop CP, Kreienkamp HJ, Richter D. Agonist-independent internalization and activity of a C-terminally truncated somatostatin receptor subtype 2 (delta349). J Neurochem. 1999;72:1275-1282.
42. Ben-Shlomo A, Pichurin O, Barshop NJ, et al. Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation. Mol Endocrinol. 2007;21:2565-2578.
43. Kvanta A. Ocular angiogenesis: the role of growth factors. ActaOphthalmol Scand. 2006;84:282-288.
44. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease.Prog Retin Eye Res. 2003;22:1-29.
45. Goldenberg-Cohen N, Dadon S, Avraham BC et al. Molecular and histological changes following central retinal artery occlusion in a mouse model. Exp Eye Res. 2008;87:327-333.
46. Kaur C, Sivakamur V, Foulds WS. Early response of neurons and glial cells to hypoxia in the retina. Invest Ophthalmol Vis Sci.2006;47:1126-1141.
47. Werdich XQ, McCollum GW, Rajaratnam VS, Penn JS. Variable oxygen and retinal VEGF levels: correlation with incidence and severity of pathology in a rat model of oxygen-induced retinopathy. Exp Eye Res. 2004;79:623-630.
48. McLeod DS, Taomoto M, Cao J, Zhu Z, Witte L, Lutty GA. Localization of the VEGF receptor-2 (KDR/Flk-1) and effects of blocking it in oxygen-induced retinopathy. Invest Ophthalmol Vis Sci.2002;43:474-482.
49. Mentlein R, Eichler O, Forstreuter F, Held-Feindt J. Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int J Cancer. 2001;92:545-550.
50. Sall JW, Klisovic DD, O'Dorisio MS, Katz SE. Somatostatin inhibits IGF-1 mediated induction of VEGF in human retinal pigment epithelial cells. Exp Eye Res. 2004;79:465-476.
51. Lawnicka H, Pisarek H, Kunert-Radek J, Pawlikowski M. Effects of somatostatin on vascular endothelial growth factor (VEGF) secretion from non-functioning pituitary tumoral cells incubated in vitro. Neuro Endocrinol Lett. 2008;29:113-116.
52. Casini G, Catalani E, Dal Monte M, Bagnoli P. Functional aspects of the somatostatinergic system in the retina and the potential therapeutic role of somatostatin in retina disease. Histol Histopathol.2005;20:615-632.
53. Watson JC, Balster DA, Gebhardt BM, et al. Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br J Cancer. 2001;85:266-272.
54. Adams RL, Adams IP, Lindow SW, Zhong W, Atkin SL. Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br J Cancer. 2005;92:1493-1498.
55. Lambooij AC, Kuijpers RW, van Lichtenauer-Kaligis EG, et al. Somatostatin receptor 2A expression in choroidal neovascularization secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2000;41:2329-2335.
56. van Hagen PM, Baarsma GS, Mooy CM, et al. Somatostatin and somatostatin receptors in retinal diseases. Eur J Endocrinol. 2000; 143(suppl 1):S43-S51.
57. Bradley J, Ju M, Robinson GS. Combination therapy for the treatment of ocular neovascularization. Angiogenesis. 2007;10:141-148.